PPARG and type 2 diabetes mellitus: A similar discrepancy has been observed with thiazolidinediones that act through the nuclear receptor PPARG.76, 77 Clinical trials implicated that rosiglitazone increases the risk of obesity, congestive heart failure and myocardial infarction in patients who received the drug for type 2 diabetes mellitus,78, 79, 80 while it was capable of increasing the thermogenic competency of WAT in mice7 and inducing browning of human adipocytes ex vivo.41 Our data suggest that adipocytes differentiated in the presence of clozapine are less sensitive to cAMP stimulation.